Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients
G. Iatrakis1, C. Iavazzo2,*, S. Zervoudis3, A. Koumousidis4, C. Sofoudis2, T. Kalampokas2, N. Salakos2
1 Technological Educational Institute of Athens, School of Midwifery, Athens
2 Family Planning Unit, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, University of Athens Medical School, Athens
3 LITO Hospital, department of Gynecological Oncology, Athens
4 Department of Obstetrics and Gynecology, Tzaneio Hospital, Piraeus (Greece)
Clin. Exp. Obstet. Gynecol. 2011, 38(3), 225–227;
Published: 10 September 2011
The investigation of potential predisposing factors of breast cancer, a disease accounting for almost one-third of malignancies in women, is necessary in order to reduce the incidence. Materials and Method: We interviewed 405 female patients who had been diagnosed with breast cancer and who also reported having used oral contraceptive pills before. They were categorized into two groups (group A < 7 years OC use and group B > 7 years OC use). Results: Statistical analysis revealed a small (p < 0.02) but significant increased risk of the disease to BRCA mutation carriers, as well as to the women with a significant medical or family history of breast, ovarian or colon cancer who had also previously used oral contraceptive pills for more than seven years. Discussion: Breast cancer seems to be positively dependent on prolonged oral contraceptive use. Conclusion: More research is needed to establish the hypothesis that the human genome is vulnerable to oral contraceptives.
BRCA mutation carriers